Methods and compositions for treatment of skin disorders

Abstract

The invention provides methods and compositions for the treatment of a skin disorder associated with detrimental TNFα activity, such as psoriasis. The invention includes methods for treating a skin disorder associated with detrimental TNFα activity, such as psoriasis, in a subject who has failed or lost response to prior biologic therapy, such as prior administration of etanercept. The invention further provides methods for determining the efficacy of a human TNFα antibody, or antigen-binding portion thereof, for the treatment of a skin disorder associated with detrimental TNFα activity, such as psoriasis.

1 . A method for treating a skin disorder associated with detrimental TNFα activity in a subject who has failed to respond to or has lost responsiveness to a biologic therapy, comprising administering to the subject who has failed to respond to or has lost responsiveness to the biologic therapy, a human TNFα antibody, or an antigen-binding portion thereof, such that the skin disorder is treated. 
     
     
         2 . A method of determining the efficacy of a human TNFα antibody, or an antigen binding portion thereof, for treating psoriasis in a subject who has failed to respond to or has lost responsiveness to a biologic therapy comprising,
 determining the PASI50 response of a patient population who has failed to respond to or has lost responsiveness to a biologic therapy, and who were administered the human TNFα antibody, or antigen binding portion thereof, 
 wherein a statistically significant improvement in the PASI50 of the patient population indicates that the TNFα inhibitor is effective for treating psoriasis in the subject.